PedAM
Pediatric Disease Annotations & Medicines
| multiple chemical sensitivity | ||||
| Disease ID | 1135 |
|---|---|
| Disease | multiple chemical sensitivity |
| Definition | An acquired disorder characterized by recurrent symptoms, referable to multiple organ systems, occurring in response to demonstrable exposure to many chemically unrelated compounds at doses below those established in the general population to cause harmful effects. (Cullen MR. The worker with multiple chemical sensitivities: an overview. Occup Med 1987;2(4):655-61) |
| Synonym | chem sensitivities multiple chem sensitivity multiple chemical multiple sensitivity chemical sensitivities, multiple chemical sensitivity, multiple chemicals multiple sensitivity environmental intolerance, idiopathic environmental intolerances, idiopathic idiopathic envir intolerance idiopathic envir intolerances idiopathic environmental intolerance idiopathic environmental intolerance (disorder) idiopathic environmental intolerances intolerance, idiopathic environmental intolerances, idiopathic environmental multiple chem sensitivities multiple chem sensitivity multiple chem sensitivity syndrome multiple chemical sensitivities multiple chemical sensitivity [disease/finding] multiple chemical sensitivity syndrome sensitivities multiple chem sensitivities, multiple chemical sensitivity multiple chem sensitivity, multiple chemical |
| DOID | |
| UMLS | C0242992 |
| MeSH | |
| SNOMED-CT | |
| Comorbidity | UMLS | Disease | Sentences' Count(Total Sentences:2) |
| Curated Gene | Entrez_id | Symbol | Resource(Total Genes:1) |
| Inferring Gene | Entrez_id | Symbol | Resource(Total Genes:16) 887 | CCKBR | infer 1557 | CYP2C19 | infer 1559 | CYP2C9 | infer 1565 | CYP2D6 | infer 1577 | CYP3A5 | infer 2944 | GSTM1 | infer 2950 | GSTP1 | infer 2952 | GSTT1 | infer 4524 | MTHFR | infer 9 | NAT1 | infer 10 | NAT2 | infer 5444 | PON1 | infer 5445 | PON2 | infer 6532 | SLC6A4 | infer 6648 | SOD2 | infer 54658 | UGT1A1 | infer |
| Text Mined Gene | Entrez_id | Symbol | Score | Resource(Total Genes:45) 5444 | PON1 | DISEASES 5445 | PON2 | DISEASES 1577 | CYP3A5 | DISEASES 55907 | CMAS | DISEASES 2946 | GSTM2 | DISEASES 5184 | PEPD | DISEASES 7355 | SLC35A2 | DISEASES 3315 | HSPB1 | DISEASES 2952 | GSTT1 | DISEASES 1215 | CMA1 | DISEASES 1559 | CYP2C9 | DISEASES 9360 | PPIG | DISEASES 6532 | SLC6A4 | DISEASES 217 | ALDH2 | DISEASES 6521 | SLC4A1 | DISEASES 29899 | GPSM2 | DISEASES 1371 | CPOX | DISEASES 5443 | POMC | DISEASES 7375 | USP4 | DISEASES 1392 | CRH | DISEASES 10 | NAT2 | DISEASES 6285 | S100B | DISEASES 4846 | NOS3 | DISEASES 54578 | UGT1A6 | DISEASES 8988 | HSPB3 | DISEASES 54658 | UGT1A1 | DISEASES 9836 | LCMT2 | DISEASES 2944 | GSTM1 | DISEASES 6863 | TAC1 | DISEASES 3992 | FADS1 | DISEASES 4843 | NOS2 | DISEASES 887 | CCKBR | DISEASES 9138 | ARHGEF1 | DISEASES 1565 | CYP2D6 | DISEASES 6648 | SOD2 | DISEASES 7432 | VIP | DISEASES 4803 | NGF | DISEASES 1557 | CYP2C19 | DISEASES 4524 | MTHFR | DISEASES 594857 | NPS | DISEASES 2950 | GSTP1 | DISEASES 7442 | TRPV1 | DISEASES 4908 | NTF3 | DISEASES 83857 | TMTC1 | DISEASES 3316 | HSPB2 | DISEASES |
| Locus | (Waiting for update.) |
| Disease ID | 1135 |
|---|---|
| Disease | multiple chemical sensitivity |
| Integrated Phenotype | (Waiting for update.) |
| Text Mined Phenotype | HPO | Name | Sentences' Count(Total Phenotypes:3) |
| Disease ID | 1135 |
|---|---|
| Disease | multiple chemical sensitivity |
| Manually Symptom | (Waiting for update.) |
| Text Mined Symptom | (Waiting for update.) |
Manually Genotype(Total Text Mining Genotypes:0) |
|---|
| (Waiting for update.) |
All Snps(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Annotation(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Snp Trait(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
Mapped by lexical matching(Total Items:0) |
|---|
| (Waiting for update.) |
Mapped by homologous gene(Total Items:0) |
|---|
| (Waiting for update.) |
Chemical(Total Drugs:2) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
| C0242992 | acetaminophen | D000082 | 103-90-2 | multiple chemical sensitivity | MESH:D018777 | marker/mechanism | 17075259 | ||
| C0242992 | lindane | D001556 | 58-89-9 | multiple chemical sensitivity | MESH:D018777 | marker/mechanism | 8766847 | ||
FDA approved drug and dosage information(Total Drugs:4) | ||||||||
|---|---|---|---|---|---|---|---|---|
| DiseaseID | Drug_name | active_ingredients | strength | Dosage Form/Route | Marketing Status | TE code | RLD | RS |
| MESH:D018777 | ofirmev | acetaminophen | 1GM/100ML (10MG/ML) | SOLUTION;IV (INFUSION) | Prescription | AP | Yes | Yes |
| MESH:D018777 | ofirmev | acetaminophen | 1GM/100ML (10MG/ML) | SOLUTION;IV (INFUSION) | Prescription | AP | Yes | Yes |
| MESH:D018777 | acetaminophen | acetaminophen | 650MG | SUPPOSITORY;RECTAL | Over-the-counter | None | Yes | Yes |
| MESH:D018777 | acetaminophen | acetaminophen | 650MG | SUPPOSITORY;RECTAL | Over-the-counter | None | Yes | Yes |
FDA labeling changes(Total Drugs:4) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiseaseID | Pediatric_Labeling_Date | Trade_Name | Generic_Name_or_Proper_Name | Indications Studied | Label Changes Summary | Product Labeling | BPCA(B) | PREA(P) | BPCA(B) and PREA(P) | Pediatric Rule (R) | Sponsor | Pediatric Exclusivity Granted Date | NNPS |
| MESH:D018777 | 2/11/2010 | ofirmev | acetaminophen | Management of mild-to-moderate pain, for the management of moderate-to-severe pain with adjunctive opioid analgesics, and for the reduction of fever | The safety and effectiveness of Ofirmev for the treatment of acute pain and fever in pediatric patients ages 2 years and older is supported by evidence from adequate and well-controlled studies of Ofirmev in adults. Additional safety and PK data was collected in 355 from premature neonates to adolescents. The effectiveness of Ofirmev for the treatment of acute pain and fever has not been studied in pediatric patients < 2 years of age.The PK exposure of Ofirmev observed in children and adolescents is similar to adults, but higher in neonates and infants. Dosing simulations from PK data in infants and neonates suggest that dose reductions of 33% in infants 1 month to < 2 years of age, and 50% in neonates up to 28 days, with a minimum dosing interval of 6 hours, will produce a PK exposure similar to that observed in children age 2 years and olderMost common adverse reactions in pediatric patients were nausea, vomiting, constipation, pruritus, agitation, and atelectasis.Information on dosing, clinical studies, adverse reactions and PK parametersNew dosage form and route of administration | Labeling | - | P | - | - | Cadence | - | FALSE' |
| MESH:D018777 | 01/27/2017 | ofirmev | acetaminophen | Treatmeny of pain and fever in pediatric patients birth to 2 years | Treatment of pain Efficacy was not demonstrated in pediatric patients younger than 2 years in a double-blind, placebo-controlled study of 198 pediatric patients younger than 2 years. Pediatric patients less than 2 years of age, including neonates from 28 to 40 weeks gestational age at birth, were randomized to receive opioid plus acetaminophen or opioid plus placebo. No difference in analgesic effect of intravenous acetaminophen, measured by assessment of reduced need for additional opioid treatment for pain control, was observed. Treatment of fever The safety and effectiveness for the treatment of fever in pediatric patients, including premature neonates born at 32 weeks or greater gestation is supported by adequate and well-controlled studies of Ofirmev in adults, clinical studies in 244 pediatric patients 2 years and older, and safety and pharmacokinetic data from 239 patients younger than 2 years including neonates 32 weeks or greater gestational age. Information on dosing, clinical trials. Postmarketing study. | Labeling | - | - | B,P | - | Mallinckrodt | 11/7/2016 | FALSE |
| MESH:D018777 | 2/11/2010 | ofirmev | acetaminophen | Management of mild-to-moderate pain, for the management of moderate-to-severe pain with adjunctive opioid analgesics, and for the reduction of fever | The safety and effectiveness of Ofirmev for the treatment of acute pain and fever in pediatric patients ages 2 years and older is supported by evidence from adequate and well-controlled studies of Ofirmev in adults. Additional safety and PK data was collected in 355 from premature neonates to adolescents. The effectiveness of Ofirmev for the treatment of acute pain and fever has not been studied in pediatric patients < 2 years of age.The PK exposure of Ofirmev observed in children and adolescents is similar to adults, but higher in neonates and infants. Dosing simulations from PK data in infants and neonates suggest that dose reductions of 33% in infants 1 month to < 2 years of age, and 50% in neonates up to 28 days, with a minimum dosing interval of 6 hours, will produce a PK exposure similar to that observed in children age 2 years and olderMost common adverse reactions in pediatric patients were nausea, vomiting, constipation, pruritus, agitation, and atelectasis.Information on dosing, clinical studies, adverse reactions and PK parametersNew dosage form and route of administration | Labeling | - | P | - | - | Cadence | - | FALSE' |
| MESH:D018777 | 01/27/2017 | ofirmev | acetaminophen | Treatmeny of pain and fever in pediatric patients birth to 2 years | Treatment of pain Efficacy was not demonstrated in pediatric patients younger than 2 years in a double-blind, placebo-controlled study of 198 pediatric patients younger than 2 years. Pediatric patients less than 2 years of age, including neonates from 28 to 40 weeks gestational age at birth, were randomized to receive opioid plus acetaminophen or opioid plus placebo. No difference in analgesic effect of intravenous acetaminophen, measured by assessment of reduced need for additional opioid treatment for pain control, was observed. Treatment of fever The safety and effectiveness for the treatment of fever in pediatric patients, including premature neonates born at 32 weeks or greater gestation is supported by adequate and well-controlled studies of Ofirmev in adults, clinical studies in 244 pediatric patients 2 years and older, and safety and pharmacokinetic data from 239 patients younger than 2 years including neonates 32 weeks or greater gestational age. Information on dosing, clinical trials. Postmarketing study. | Labeling | - | - | B,P | - | Mallinckrodt | 11/7/2016 | FALSE |